# Cladder-Micus_2018_Mindfulness-based cognitive therapy for patients with chronic, treatment-resistant depression A pragmatic randomized controlled trial.

Received: 30 August 2017

Revised: 25 May 2018

Accepted: 29 May 2018

DOI: 10.1002/da.22788

R E S E A R C H A R T I C L E

Mindfulness-based cognitive therapy for patients with chronic,
treatment-resistant depression: A pragmatic randomized
controlled trial

Mira B. Cladder-Micus1,2,3

Anne E.M. Speckens3

Janna N. Vrijsen2,4

A. Rogier T. Donders5

Eni S. Becker1

Jan Spijker1,2

1Behavioural Science Institute, Radboud Univer-
sity Nijmegen, Nijmegen, The Netherlands

2Depression Expertise Centre, Pro Persona
Mental Health Care, Nijmegen, The Netherlands

3Department of Psychiatry, Radboud University
Medical Center, Nijmegen, The Netherlands

4Department of Psychiatry, Donders Insti-
tute for Brain, Cognition and Behaviour, Rad-
boud University Medical Center, Nijmegen, The
Netherlands

5Department for Health Evidence, Radboud
University Medical Center, Nijmegen,
The Netherlands

Correspondence
Mira B. Cladder-Micus, Department of Psychi-
atry, Radboud University Medical Center, P.O.
Box 9101, Internal Postal Code 966, 6500 HB
Nijmegen, The Netherlands.
Email: m.cladder-micus@psych.ru.nl

Funding information
Fonds Psychische Gezondheid, Grant/Award
Number: 2011 6630

Background: Chronic and treatment-resistant depressions pose serious problems in mental

health care. Mindfulness-based cognitive therapy (MBCT) is an effective treatment for remitted

and currently depressed patients. It is, however, unknown whether MBCT is effective for chronic,

treatment-resistant depressed patients.

Method: A pragmatic, multicenter, randomized-controlled trial was conducted comparing
treatment-as-usual (TAU) with MBCT + TAU in 106 chronically depressed outpatients who pre-
viously received pharmacotherapy (‚â•4 weeks) and psychological treatment (‚â•10 sessions).

Results: Based on the intention-to-treat (ITT) analysis, participants in the MBCT + TAU condi-

tion did not have significantly fewer depressive symptoms than those in the TAU condition (‚Äì3.23
[‚Äì6.99 to 0.54], d = 0.35, P = 0.09) at posttreatment. However, compared to TAU, the MBCT + TAU
group reported significantly higher remission rates (ùúí 2(2) = 4.25, ùúë = 0.22, P = 0.04), lower levels
of rumination (‚Äì3.85 [‚Äì7.55 to ‚Äì0.15], d = 0.39, P = 0.04), a higher quality of life (4.42 [0.03‚Äì8.81],
d = 0.42, P = 0.048), more mindfulness skills (11.25 [6.09‚Äì16.40], d = 0.73, P < 0.001), and more
self-compassion (2.91 [1.17‚Äì4.65], d = 0.64, P = 0.001). The percentage of non-completers in the
MBCT + TAU condition was relatively high (n = 12, 24.5%). Per-protocol analyses revealed that
those who completed MBCT + TAU had significantly fewer depressive symptoms at posttreat-
ment compared to participants receiving TAU (‚Äì4.24 [‚Äì8.38 to ‚Äì0.11], d = 0.45, P = 0.04).

Conclusion: Although the ITT analysis did not reveal a significant reduction in depressive symp-
toms of MBCT + TAU over TAU, MBCT + TAU seems to have beneficial effects for chronic,

treatment-resistant depressed patients in terms of remission rates, rumination, quality of life,

mindfulness skills, and self-compassion. Additionally, patients who completed MBCT showed

significant reductions in depressive symptoms. Reasons for non-completion should be further

investigated.

K E Y W O R D S

depressive disorder, mindfulness, quality of life, randomized controlled trial, treatment-resistant

depression

1

INTRODUCTION

2000). Chronic depression not only affects the personal life of a

patient, but is also associated with high costs for society in terms of

Major depressive disorder is one of the leading causes of disability

health care costs and workplace losses (Pincus, 2001). Unfortunately,

worldwide (Lopez, Mathers, Ezzati, Jamison, & Murray, 2006). Despite

a large number of chronically depressed patients do not respond

evidence-based treatments, about 20% of all depressed patients

to treatment (Torpey & Klein, 2008). Therefore, novel treatment

develop a chronic course (Kessler et al., 2003), typically defined as

strategies for this severely ill population are much needed (Cuijpers,

a period of 2 years or longer of depressive symptoms (DSM-IV-TR,

Huibers, & Furukawa, 2017).

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
c(cid:2) 2018 The Authors. Depression and Anxiety published by Wiley Periodicals, Inc.

914

wileyonlinelibrary.com/journal/da

Depress Anxiety. 2018;35:914‚Äì924.

CLADDER-MICUS ET AL.

915

Surprisingly, no unified definition of treatment-resistant depres-

sion exists. Staging methods to measure treatment resistance mostly

The aim of the current study was to investigate the effectiveness
of MBCT + TAU versus TAU only for chronically depressed patients

focus on the number of biological treatment steps (Trevino, McClin-

with current moderate to severe depressive symptoms who have

tock, Fischer, Vora, & Husain, 2014). In line with these staging methods,

not responded to previous pharmacotherapy and evidenced-based

most clinical trials define a depressive episode as treatment-resistant

psychological treatments, that is, cognitive behavioral therapy (CBT)

if two or more trials with antidepressant medication were unsuccess-

or interpersonal therapy (IPT). The primary outcome measure was

ful (Rush, Thase, & Dub√©, 2003; Trevino et al., 2014). However, this

the level of depressive symptoms. Secondary outcome measures were

definition conflicts with multidisciplinary treatment guidelines (NICE,

remission rates, rumination, quality of life, mindfulness skills, and

2009), which state that depressed patients with moderate to severe

self-compassion. Additionally, we examined the following variables

symptoms should receive a combination of psychological and phar-

as potential moderators of treatment effect gender, age, childhood

macological treatments. Therefore, a new staging method to measure

trauma, number of previous episodes, duration of current depressive

treatment resistance was developed, which is termed as the ‚ÄúDutch

episode, treatment resistance, baseline levels of depressive symptoms,

Measure for quantification of Treatment Resistance in Depression‚Äù

rumination, mindfulness skills, and self-compassion.

(DM-TRD) (Peeters et al., 2016). In contrast to previous staging meth-

ods (Fekadu, Wooderson, Donaldson, et al., 2009; Fekadu, Wooder-

son, Markopoulou, & Cleare, 2009; Petersen et al., 2005; Souery et al.,

1999; Thase & Rush, 1997), the DM-TRD not only focuses on biolog-

2 METHOD

ical treatments but also includes evidence-based psychological treat-

ments. For these reasons, we have chosen to apply the criteria of the

2.1 Design

DM-TRD for treatment resistance in the current study.

Mindfulness-based cognitive therapy (MBCT) is an 8-week group

This trial was an open-labeled, multicenter RCT comparing two groups:
MBCT + TAU and TAU. Methods and procedures are fully described

training that combines mindfulness meditation techniques with ele-

in the published protocol (Cladder-Micus et al., 2015) and are sum-

ments of cognitive-behavioral therapy (Segal, Williams, & Teasdale,

marized below. All participants gave written informed consent and

2012). MBCT teaches participants to recognize and disengage from

the study was approved by the Medical Ethical Committee Arnhem-

maladaptive automatic cognitive patterns, and to develop a nonjudg-

Nijmegen (number 2012/339).

mental and compassionate attitude toward their own cognitions and

feelings. MBCT has been demonstrated to be effective in reducing

relapse (Kuyken et al., 2016). In addition, it has been shown that

2.2

Participants

MBCT reduces depressive symptoms in currently depressed patients

Participants (N = 106) were recruited at different locations of a

(Strauss, Cavanagh, Oliver, & Pettman, 2014). Preliminary studies

local mental health institute (Pro Persona) and a university medical

(Barnhofer Crane, Hargus, Amarasinghe, Winder, & Williams, 2009;

center (Radboud University Medical Center, Centre for Mindful-

Eisendrath et al., 2008; Kenny & Williams, 2007) have even found

ness). Participants were referred by mental health care professionals

beneficial effects of MBCT for patients with chronic or treatment-

or recruited via flyers, posters, and websites. Clinicians were also

resistant depression. In line with these findings, in a recent random-

explicitly asked to screen their caseload for potentially eligible par-

ized controlled trial (RCT) of Eisendrath et al. (2016) in treatment-

resistant depressed patients, MBCT was demonstrated to be superior

to an active control group matched on treatment intensity. However,

partly contrasting results were found by Michalak, Probst, Heidenre-

ich, Bissantz, and Schramm (2016) in an RCT comparing MBCT with

Cognitive Behavioural Analysis System of Psychotherapy (CBASP) and

treatment-as-usual (TAU) in chronically depressed patients. CBASP

ticipants. A depressive episode was defined as ‚Äúchronic‚Äù if symptoms
persisted for ‚â•12 months, because research has shown that chances

of recovery decrease substantially after this period (Spijker et al.,
2002). Inclusion criteria were (a) age ‚â• 18, (b) current depressive
episode according to DSM-IV criteria with a duration of ‚â•12 months,

(c) moderate to high levels of depressive symptoms (Inventory of
Depressive Symptomatology-Self-Report [IDS-SR] ‚â• 21), (d) at least

is a psychological treatment with a strong interpersonal orientation

one adequate trial of antidepressant medication during the current

that focuses on overcoming the learned helplessness of the patient

by teaching patients that their own behavior affects others and them-

episode (defined as appropriate doses of antidepressant medication
for ‚â•4 weeks or patient's refusal to use medication contrary to the

selves (McCullough, 2003). Michalak et al. (2016) concluded that

MBCT was inferior to CBASP, and MBCT was superior to TAU only at

one treatment site.

advice of a psychiatrist), and (e) previous psychological treatment
during the current episode (defined as ‚â•10 sessions of CBT or IPT
or < 10 sessions if discontinued because of patient's withdrawal).

Importantly, all available controlled studies about MBCT for

Exclusion criteria were as follows: (a) current psychotic symptoms;

treatment-resistant depression focused on pharmacoresistant

depressed patients (Eisendrath et al., 2008, 2016).

It therefore

(b) lifetime bipolar disorder; (c) current alcohol or drug dependence;
(d) recent electro convulsive therapy (< 3 months ago); (e) current

remains unclear whether MBCT is effective in chronically depressed

somatic disorder partly explaining depressive symptoms; (f) physical,

patients who have been treated according to treatment guidelines (i.e.,

linguistic, cognitive, or intellectual impairments, which might interfere

received evidence-based psychological treatment and pharmacother-

with participation in MBCT or assessments; and (g) previous MBCT

apy) but have not responded.

training. Baseline characteristics can be found in Table 1.

916

CLADDER-MICUS ET AL.

TA B L E 1 Demographic characteristics, clinical characteristics, and
baseline levels of symptoms in both conditions displayed as number
(percentage) unless otherwise specifieda

Whole sample TAU

MBCT + TAU

n = 106

n = 57

n = 49

Demographic characteristics

Female

66 (62)

34 (60)

32 (65)

Age, M (SD), years

47.1 (10.25)

47.33 (10.9)

46.86 (9.53)

TA B L E 1

(Continued)

Whole sample TAU

MBCT + TAU

n = 106

n = 106

n = 57

n = 57

n = 49

n = 49

13.92 (2.73)

14.08 (2.71)

13.74 (2.77)

n = 89

n = 52

n = 37

49.22 (19.48)

48.77 (17.80) 49.86 (21.64)

Treatment-resistance
(DM-TRD), M (SD)

Childhood trauma
(CTQ), M (SD)

Education

Low

Medium

High

Marital status

34 (32)

29 (27)

35 (33)

18 (32)

20 (35)

18 (32)

16 (32)

9 (18)

17 (35)

Baseline assessment, M (SD)

n = 106

n = 57

n = 49

Depression (IDS-SR)

41.11 (9.37)

42.21 (9.12)

39.83 (9.59)

n = 100

n = 57

n = 43

Single/widowed/

45 (43)

28 (49)

17 (35)

Rumination (RRS)

56.82 (9.89)

56,89 (10.12) 56.75 (9.69)

divorced

Married/

cohabitating

Employment

Full time

Part time

44 (42)

24 (42)

20 (41)

10 (9.4)

19 (17.9)

7 (12.3)

7 (12.3)

3 (6.1)

12 (24.5)

Unemployed

67 (63.2)

40 (70.2)

27 (55.1)

Retired

3 (2.8)

1 (1.8)

1 (2)

n = 104

n = 56

n = 48

2.69 (3.37)

2.68 (3.96)

2.71 (2.56)

29.84 (13.16)

31.75 (12.70) 27.61 (13.48)

n = 103

n = 56

n = 47

63.59 (70.74)

60.54 (65.42) 67.23 (77.76)

85 (80)

45 (79)

40 (82)

50 (47)

n = 97

30 (53)

n = 53

20 (41)

n = 44

Brooding

Reflective

13.54 (2.94)

13,57 (3.08)

13.51 (2.77)

10.79 (3.09)

10,80 (3.37)

10.79 (2.71)

Quality of life
(WHOQoL-BREF)

71.92 (10.24)

70,97 (8.97)

73.18 (11.72)

Physical

18.87 (4.07)

18,59 (3.28)

19.23 (4.94)

Psychological

13.67 (3.07)

13,50 (2.95)

13.88 (3.23)

Social

8.67 (2.34)

8,52 (2.23)

8.86 (2.49)

Environment

26.15 (4.03)

25,82 (3.90)

26.60 (4.22)

Mindfulness (FFMQ)

n = 99

101.21
(15.27)

n = 56

100.92
(15.34)

n = 43

101.60
(15.35)

Observing

Describing

21.37 (5.67)

21.27 (5.73)

21.51 (5.66)

22.50 (6.57)

22.24 (5.64)

22.86 (7.69)

Acting/awareness

19.23 (4.86)

19.18 (4.79)

19.30 (5.04)

Nonjudging

21.37 (6.40)

21.65 (6.78)

21.01 (5.92)

Nonreacting

16.92 (3.91)

16.94 (4.24)

16.31 (3.50)

Self-compassion
(SCS)

n = 98

n = 56

n = 42

17.59 (4.61)

17.63 (5.16)

17.55 (3.88)

Self-kindness

2.67 (1.11)

2.68 (1.14)

2.67 (1.09)

36.29 (49.69)

32.94 (36.27) 40.32 (62.38)

Self-judging

2.99 (1.26)

2.98 (1.28)

3.01 (1.27)

13 (23)

8 (14)

36.8

14 (25)

12 (21)

13 (23)

1 (2)

1 (2)

7 (14)

7 (14)

40.8

9 (18)

8 (16)

11 (22)

2 (4)

3 (6)

Common humanity 3.01 (1.09)

2.99 (1.13)

3.05 (1.06)

Isolation

2.73 (1.07)

2.79 (1.23)

2.64 (0.81)

Mindfulness

3.17 (1.15)

3.05 (1.45)

3.33 (1.15)

Overidentification

3.03 (1.23)

3.18 (1.34)

2.83 (1.10)

serotonin; TCA,

Note. AD, antidepressant; CBT, cognitive behavioral therapy; IPT, interper-
sonal therapy; MAOI, monoamine-oxidase inhibitor; SNRI, serotonin‚Äì
norepinephrine reuptake inhibitor; SSRI,
tricyclic
antidepressant;
Inventory of Depressive Symptomatology-
IDS-SR,
Self Report; WHOQoL-BREF, World Health Organisation Quality of
Life Questionnaire; FFMQ, Five Facets Mindfulness Questionnaire; SCS,
Self-Compassion Scale.
aThere were no significant differences between the MBCT + TAU and TAU
condition.
bCurrent depressive episode.
cAt baseline, according to DSM-IV criteria.

Clinical characteristics

Previous episodes, M
(SD)

Age of onset, M (SD),
years

Duration episodeb, M
(SD), months

Current episode ‚â• 2
years

Anxiety disorderc

Psychological
treatment sessions
(CBT/IPT)b, M (SD)

Previous inpatient treatment b

Inpatient

Day-hospital

> 2 AD's current
episode (%)

20 (19)

15 (14)

38.7

Medication level at baseline

No AD

1 SSRI

23 (22)

20 (19)

1 TCA/SNRI/other

24 (23)

AD

1 MAOI

2 AD's

1 AD +

antipsychotic

3 (3)

4 (4)

21 (20)

11 (19)

10 (20)

1 AD + lithium

7 (7)

4 (7)

3 (6)

(Continues)

CLADDER-MICUS ET AL.

2.3

Procedure

Interested patients received an information letter and were contacted

via telephone. During a subsequent research interview, the Mini Inter-

national Neuropsychiatric Interview (MINI, Sheehan et al., 1998) was

administered to diagnose depressive, anxiety, psychotic, and addictive

disorders according to DSM-IV criteria. In addition, sociodemographic

and clinical characteristics were assessed, including treatment resis-

tance (DM-TRD, Peeters et al., 2016) and childhood trauma (Childhood

Trauma Questionnaire; Bernstein et al., 2003). The DM-TRD includes

domains such as duration and severity of symptoms, comorbid anxiety

disorders, functional impairments, previous biological treatments, and

previous psychological treatments. After completion of the baseline
measures, participants were randomized to MBCT + TAU or TAU only

by means of a web-based application that was specifically designed for

this study by an independent statistician. Randomization was 1:1 to
MBCT + TAU or TAU only, stratified for treatment center, and mini-

mized for the severity of depressive symptoms (IDS-SR: 21‚Äì31; 32‚Äì
39; > 40) and chronicity (1‚Äì2 years, ‚â•2 years), without using block ran-

domization. If due to scheduling constraints the time between base-

line assessment and start of MBCT exceeded 4 weeks, a second base-

line assessment was conducted before MBCT started. Participants

assigned to the TAU condition were offered MBCT after completion

of posttreatment measures. Follow-up data were collected at 3 and 6
months after completing MBCT. Additionally, a subsample (N = 86) was

invited to participate in experimental tasks during baseline and post-

treatment to assess biased information processing. These data focus

on different research questions and will be presented separately. Data

presented here were collected between January 2013 and April 2016.

2.4

Interventions

2.4.1 MBCT + TAU

MBCT was based on the manual by Segal, Williams, and Teasdale

(2002) and consisted of 8 weekly 2.5-hr sessions and 1 day of prac-

tice (day of silence). Participants were enrolled in MBCT courses that

were part of the regular treatment program for patients with depres-

sive disorders. The average number of study participants was 2.41
(SD = 1.55) per MBCT group of 8‚Äì12 patients. Mindfulness train-

ers were informed about enrollment of participants in the study, but

were pressed to adopt an identical approach and procedure for all

patients. Group members were not informed about study participa-

tion of individual fellow members, but participants were of course

allowed to share this information at will. All mindfulness trainers were

highly experienced in working with depressed patients and had com-

pleted a postgraduate 2-year mindfulness teacher training. Thereby

they met the advanced criteria of good practice guidelines of the UK

Network for Mindfulness-Based Teachers (Network, 2011). Teacher

competence and adherence was assessed with the Mindfulness-Based

Interventions-Teaching Assessment Criteria (Crane et al., 2012) based

on two video recorded sessions per trainer. Two independent mindful-

917

(who trained, respectively, two and three participants) were unavail-

able. Participants received TAU in conjunction with MBCT.

2.4.2

TAU

Treatment-as-usualTAU was a naturalistic condition consisting of

mental health care for depression, including antidepressant medica-

tion, psychological treatment, support by a psychiatric nurse, or day-

hospital treatment. There were no significant differences between

conditions in the mean number of treatment sessions or in the num-

ber of patients who received these treatments (see Table 2). Medica-

tion levels at baseline can be found in Table 1. A minority of participants

changed in medication level. This information is summarized in Table 2

and additional information can be found in the Supporting Information

Table 1.

2.5 Outcome measures

2.5.1

Primary outcome measure

The primary outcome was the level of depressive symptoms assessed

with IDS-SR (Rush, Gullion, Basco, Jarrett, & Trivedi, 1996). The IDS-SR

has good psychometric properties (Rush et al., 1996). The IDS-SR has

previously been used in research on MBCT and is sensitive to change

(Geschwind, Peeters, Huibers, van Os, & Wichers, 2012). In the current
sample, the internal consistency was ùõº = 0.74.

2.5.2

Secondary outcome measures

Remission was assessed with the depression module of the MINI,

which investigates depressive symptoms according to DSM-IV crite-

ria. Remission was defined as the absence of depressive symptoms

during the last 2 weeks. Participants reporting some symptoms but

not fulfilling DSM-IV criteria according to the MINI were classified as

being in partial remission. The interviews were administered by trained

research psychologists supervised by an experienced psychiatrist (AS)

and were audio recorded. For logistical reasons, it was not possible to

keep the research psychologists blind to treatment allocation. A ran-
dom sample (n = 25) of the recorded MINI depression modules was

scored by an independent psychologist blind to condition, who was

extensively trained in the administration of the MINI. This yielded a
high interrater reliability (Cohen's kappa 0.88).

Rumination was assessed with the Ruminative Response Scale

(RRS-EXT; Raes & Hermans, 2007; Schoofs, Hermans, & Raes, 2010).

Quality of life was assessed with the World Health Organization Qual-
ity of Life scale (Skevington, Lotfy, & O'Connell, 2004). Mindfulness

skills and self-compassion were assessed with the Five Facet Mind-

fulness Questionnaire (Baer et al., 2008) and the Self-Compassion

Scale (Neff, 2003), respectively. More information about these sec-

ondary outcome measures can be found in the published study proto-

col (Cladder-Micus et al., 2015, pp. 5‚Äì6).

2.6

Statistical analysis

ness trainers rated the trainers. Mutually agreed ratings of the train-
ers were ‚Äúproficient‚Äù (n = 2), ‚Äúproficient/competent‚Äù (n = 1), ‚Äúcompe-
tent‚Äù (n = 2), and ‚Äúadvanced beginner‚Äù (n = 1). Videos of two trainers

The power calculation was based on a Cohen's d effect size of 0.53

for currently depressed patients as reported in a previous study (van
Aalderen et al., 2011). Based on an ùõº of 0.05 and power of 80%,

ùúí 2(1) = 0.256, P = 0.61

t(92) = ‚Äì0.859, P = 0.39

ùúí 2(1) = 0.178, P = 0.67

t(92) = ‚Äì0.092, P = 0.97

ùúí 2(1) = 0.626, P = 0.43

t(92) = 0.395, P = 0.69

918

CLADDER-MICUS ET AL.

TA B L E 2

Total number of participants and mean amount of therapy sessions received as treatment-as-usual (TAU) and changes in antidepres-

sant medication from baseline to posttreatment

MBCT + TAU

N

%

M

SD

TAU

N

%

M

SD

Test

Therapy sessions

Psychologist

23

46.9

4.84

6.59

30

52.6

3.86

4.37

Psychiatrist

15

30.6

0.73

1.33

20

35.1

0.72

1.09

Occupational therapist/ nurse specialist

Day care treatment

Medication

Discontinueda

Decrease in medication level

Increase in medication level

8

4

4

3

0

16.3

1.04

3.12

13

22.8

1.28

2.63

9.7

14.5b

11.21

8.2

6.1

0

1

2

1

4

1.75

12b

0

Fisher's exact: P = 0.174

t(3) = ‚Äì0.199, P = 0.855

3.5

1.8

7.0

Note. Psychologist sessions include therapy sessions lead by a registered psychologist (e.g., CBT, IPT, neuropsychological tests, schema therapy). Sessions by
a psychiatrist include check-up and advice concerning medications. Therapy sessions given by an occupational therapist/nurse specialist include therapies
such as running therapy, rehabilitation modules, and psychomotor therapy. Day care includes outpatient care provided by a mental health care institution
such as day treatment.
aAll antidepressant medication tapered to zero.
bIn days; only including participants with ‚â•1 day of day care treatment.

estimating the correlation between baseline and posttreatment scores

3

RESULTS

to be 0.5, and expecting a drop-out of 8 participants, a required sam-

ple size of 94 participants emerged (Cladder-Micus et al., 2015). For

3.1

Patient flow

the main analysis, posttreatment scores of depressive symptoms were

compared between the two conditions in an analysis of covariance

(ANCOVA), controlling for baseline scores of depression, chronicity
(1‚Äì2 years; ‚â•2 years), and treatment site. Similar analyses were con-

ducted for the secondary outcome measures, controlling for baseline
scores of the respective variable, chronicity (1‚Äì2 years; ‚â•2 years), and
treatment site. A Cohen's d effect size was calculated based on the
total group's (n = 106) standard deviation on the IDS-SR at baseline.

A statistical significance level of 0.05 was adhered to for all analyses.

Moderating effects of gender, age, childhood trauma, number of previ-

ous episodes, duration of current depressive episode treatment resis-

tance, baseline levels of depressive symptoms, rumination, mindful-

ness skills, and self-compassion were explored in the intention-to-treat

(ITT) sample by incorporating interaction effects in the models. Post-

treatment IDS-SR scores were missing for 10 participants (9.4%, TAU:
n = 5, MBCT + TAU: n = 5). There were no differences in clinical or base-

line characteristics between patients with and without posttreatment

IDS-SR scores, except that the patients with missing scores reported a
higher number of previous depressive episodes (M = 5.00, SD = 8.90,
t (102) = ‚Äì2.32, P = 0.02) than complete cases (M = 2.45, SD = 2.07).

For two patients without posttreatment scores, follow-up scores were

used. Analyses were based on an ITT approach including all available

data. Next, analyses were repeated in the per-protocol (PP) sample,
including participants of MBCT + TAU who attended ‚â•4 sessions and

participants of TAU. Sensitivity analyses were performed by imputing

missing data according to the last observation carried forward (LOCF)

technique. IBM SPSS statistics 22 was used to analyze the data.

Of the 213 patients who were assessed for eligibility, 111 were
interviewed and 106 were randomized over MBCT + TAU (n = 49)
and TAU (n = 57) (see Figure 1). There were no significant differ-

ences in clinical characteristics or baseline scores between the con-

ditions (see Table 1). Before entering the study, 102 participants had
received > 10 sessions of psychological treatment during the cur-

rent episode, one participant completed nine sessions during the
current depressive episode and > 10 during the previous episode,

and three participants refused psychological treatment because they
received > 10 sessions during the previous depressive episode. Five

participants refused to use antidepressant medication during the

current depressive episode against the advice of their psychiatrist.
All other participants (n = 101) had been using adequate levels of

antidepressant medication for at least 4 weeks. Twenty-six (53.0%)
MBCT + TAU participants completed a second baseline because time

from randomization to MBCT exceeded 4 weeks and no significant

changes in depressive symptoms between the first and second baseline
= 40.38,
= 41.15, SDbaseline1
= 9.99; t (25) = 0.47, P = 0.64). None of the participants

were observed (Mbaseline1
SDbaseline2
of the TAU condition took part in MBCT or other mindfulness-based
training. Twelve participants of the MBCT + TAU condition (24.5%)

= 7.86, Mbaseline2

attended fewer than four sessions of MBCT and were classified as

non-completers. The other participants (completers) attended on aver-
age 7.09 (SD = 1.15) out of the eight MBCT sessions. The most

prevalent reason for drop-out was the occurrence or deterioration of

physical problems (see Figure 1). Non-completers reported a shorter

CLADDER-MICUS ET AL.

919

F I G U R E 1 Consort flow diagram

duration of the current depressive episode (M = 60.05 months,
SD = 71.72) than completers (M = 93.18 months, SD = 56.22; U = 246.5,
P = 0.005) and they were more often unemployed (ùúí 2 (5) = 8.60,
P = 0.04). There were no other significant differences in sociodemo-

graphic or clinical characteristics between non-completers and com-

pleters (see Table 2 in the Supporting Information). No serious adverse

events occurred.

3.2

Primary outcome

Depression scores were analyzed separately for the ITT sample and the
PP sample. In both analyses, the MBCT + TAU condition showed lower

levels of depressive symptoms than TAU, with small to medium effect

sizes. However, the difference was only significant in the PP sample
(‚Äì4.24, 95% CI [‚Äì8.38 to ‚Äì0.11], d = 0.45, P = 0.04) and not in the ITT
sample (‚Äì3.23, 95% CI [‚Äì7.02 to 0.56], d = 0.35, P = 0.09) (see Table 3).

d

P

F

)
I

C
%
5
9
(

2
5
=
n
U
A
T

4
3
=
n

d

P

F

)
I

C
%
5
9
(

2
5
=
n
U
A
T

e
c
n
e
r
e
f
f
i
d
p
u
o
r
G

U
A
T
+
T
C
B
M

P
P

e
c
n
e
r
e
f
f
i
d
p
u
o
r
G

U
A
T
+
T
C
B
M

4
4
=
n

T
T
I

920

)

U
A
T
(

l
a
u
s
u
-
s
a
-
t
n
e
m
t
a
e
r
t
d
n
a
)
T
C
B
M

(
y
p
a
r
e
h
t
e
v
i
t
i
n
g
o
c
d
e
s
a
b
-
s
s
e
n
u
f
d
n
m

i

l

f
o
t
n
e
m
e
r
u
s
a
e
m
t
s
o
p
t
a
s
n
o
i
s
s
a
p
m
o
c
-
f
l
e
s
d
n
a

,

s
l
l
i

l

k
s
s
s
e
n
u
f
d
n
m
e
f
i
l

i

,

f
o
y
t
i
l
a
u
q

,

n
o
i
t
a
n
m
u
r
,

i

s
m
o
t
p
m
y
s
e
v
i
s
s
e
r
p
e
D

3

E
L
B
A
T

s
e
s
y
l
a
n
a
)

P
P

(

l

o
c
o
t
o
r
p
-
r
e
p
d
n
a
)
T
T
I
(

t
a
e
r
t
-
o
t
-
n
o
i
t
n
e
t
n

i
r
o
f

CLADDER-MICUS ET AL.

.

5
4
0

.

4
4
0
0

.

7
1
4

.

3
3
0

.

5
6
0
0

.

7
4
0

.

6
1
0
0

.

3
1
0

.

5
2
4
0

.

9
4
0

.

1
2
0
0

.

7
1
0

.

8
6
3
0

.

6
5
0

.

7
0
0
0

.

2
1
0

.

5
9
5
0

.

8
3
0

.

4
3
0
0

.

1
5
3

.

4
0
6

.

4
6
0

.

9
5
5

.

2
8
0

.

9
5
7

.

9
2
0

.

7
6
4

.

6
7
0

.

1
7
0

.

1
0
0
0
<

.

.

6
4
1
2

1
0
0
0
<

.

1
0
2
2

.

1
2
0

.

7
6
1
0

.

9
3
0

.

1
4
0
0

.

4
1
0

.

1
8
3
0

.

5
9
1

.

4
3
4

.

8
7
0

.

9
5
0

.

1
0
0
0
<

.

.

3
7
5
1

8
6
0

.

1
0
0
0

.

6
7
2
1

.

1
6
0

.

1
0
0
0

.

.

2
9
0
1

4
0
0

.

3
4
8
0

.

8
2
0

.

5
9
1
0

.

7
6
0

.

3
0
0
0

.

4
5
0

.

0
1
0
0

.

0
4
0

.

1
7
1

.

3
5
9

.

6
9
6

.

6
6
0

.

1
0
0
0

.

7
0
1
1

.

.

)
1
1
0
‚Äì
o
t
8
3
8
‚Äì
(
4
2
4
‚Äì

.

.

.

)
3
8
1
1
(
2
5
0
4

.

.

)
3
1
1
1
(
0
5
3
3

.

5
3
0

.

2
9
0
0

.

6
8
2

.

.

)
6
5
0
o
t
2
0
7
‚Äì
(
3
2
3
‚Äì

.

.

.

)
3
8
1
1
(
2
5
0
4

.

.

)
6
6
2
1
(
7
2
5
3

.

1
5
=
n

1
3
=
n

1
5
=
n

9
3
=
n

.

)
1
2
0
o
t
2
9
6
‚Äì
(
6
3
3
‚Äì

.

.

.

)
9
9
9
(
7
4
4
5

.

.

)
0
0
0
1
(
7
6
0
5

.

.

)
6
2
0
‚Äì
o
t
1
5
2
‚Äì
(
8
3
1
‚Äì

.

.

.

)
8
3
3
(
8
0
3
1

.

.

)
5
7
2
(
4
6
1
1

.

.

)
4
3
1
o
t
7
5
0
‚Äì
(
8
3
0

.

.

.

)
8
8
2
(
6
1
0
1

.

.

)
5
7
2
(
9
4
0
1

.

.

)
5
4
9
o
t
1
8
0
(
3
1
5

.

.

.

)
9
2
1
1
(
3
1
1
7

.

.

)
2
7
2
1
(
7
3
8
7

.

.

)
8
2
2
o
t
6
8
0
‚Äì
(
1
7
0

.

.

.

)
8
7
3
(
2
6
8
1

.

.

)
4
6
4
(
6
2
0
2

.

.

)
0
0
3
o
t
8
4
0
(
4
7
1

.

.

.

)
9
2
3
(
5
8
3
1

.

.

)
2
4
3
(
5
0
6
1

.

.

)
1
3
1
o
t
5
7
0
‚Äì
(
8
2
0

.

.

.

)
9
9
2
o
t
2
1
0
(
6
5
1

.

.

.

)
9
6
6
1
o
t
5
6
6
(
7
6
1
1

.

.

.

)
7
7
5
o
t
3
3
2
(
5
0
4

.

.

.

)
5
3
3
o
t
9
5
0
‚Äì
(
8
3
1

.

.

.

)
0
7
3
o
t
8
0
0
(
9
8
1

.

.

.

)
2
9
2
o
t
3
1
1
‚Äì
(
0
9
0

.

.

.

)
9
5
4
o
t
2
5
1
(
5
0
3

.

.

.

)
8
4
2
(
2
7
8

.

.

)
5
9
2
(
1
7
8

.

.

)
9
7
4
(
1
6
5
2

.

.

)
6
0
4
(
7
7
7
2

.

1
5
=
n

1
3
=
n

.

)
5
5
4
1
(
4
9
1
0
1

.

.

)
4
9
7
1
(
4
5
4
1
1

.

.

)
1
1
6
(
6
2
1
2

.

.

)
2
1
6
(
5
1
2
2

.

.

)
6
2
5
(
9
8
9
1

.

.

)
3
6
6
(
4
0
2
2

.

.

)
7
3
5
(
7
8
5
2

.

.

)
9
7
7
(
9
8
4
2

.

.

)
1
7
4
(
0
9
1
2

.

.

)
6
8
3
(
8
3
2
2

.

.

)
5
1
4
(
3
9
6
1

.

.

)
3
6
3
(
8
4
9
1

.

9
3
0

.

2
4
0
0

.

7
4
0

.

6
1
0
0

.

3
0
0

.

9
5
8
0

.

2
4
0

.

8
4
0
0

.

5
1
0

.

4
9
3
0

.

9
5
0

.

5
0
0
0

.

6
0
0

.

0
7
7
0

.

5
2
0

.

4
7
1
0

.

3
5
0

.

1
0
0
0

.

5
2
0

.

6
7
0
0

.

5
3
0

.

8
4
0
0

.

2
3
0

.

8
4
0
0

.

9
4
0

.

4
0
0
0

.

3
7
0

.

1
0
0
0
<

.

8
2
4

.

3
0
6

.

2
3
0

.

1
0
4

.

6
7
0

.

0
2
8

.

9
0

.

8
8
1

.

5
8
8
1

.

.

1
0
2
1

3
2
3

.

4
0
4

.

2
0
4

.

9
9
8

.

.

)
5
1
0
‚Äì
o
t
5
5
7
‚Äì
(
5
8
3
‚Äì

.

.

.

)
6
2
0
‚Äì
o
t
8
4
2
‚Äì
(
7
3
1
‚Äì

.

.

.

)
9
9
9
(
7
4
4
5

.

.

)
6
0
1
1
(
1
5
0
5

.

.

)
8
3
3
(
8
0
3
1

.

.

)
5
8
2
(
2
7
1
1

.

.

)
1
0
1
o
t
5
8
0
‚Äì
(
4
8
0
0

.

.

.

)
8
8
2
(
6
1
0
1

.

.

)
4
9
2
(
3
1
0
1

.

.

)
1
8
8
o
t
3
0
0
(
2
4
4

.

.

.

)
9
2
1
1
(
3
1
1
7

.

.

)
6
1
2
o
t
6
8
0
‚Äì
(
5
6
0

.

.

.

)
8
7
3
(
3
6
8
1

.

.

)
0
0
6
1
(
1
3
7
7

.

.

)
3
4
5
(
4
7
9
1

.

.

)
8
0
3
o
t
6
5
0
(
2
8
1

.

.

.

)
9
2
3
(
6
8
3
1

.

.

)
9
8
3
(
2
9
5
1

.

.

)
1
1
1
o
t
3
8
0
‚Äì
(
4
1
0

.

.

.

)
7
4
2
o
t
5
4
0
‚Äì
(
1
0
1

.

.

.

)
0
4
6
1
o
t
9
0
6
(
5
2
1
1

.

.

.

)
7
7
4
o
t
0
3
1
(
4
0
3

.

.

.

)
2
5
3
o
t
7
1
0
‚Äì
(
7
6
1

.

.

.

)
0
5
3
o
t
2
0
0
(
6
7
1

.

.

.

)
6
0
4
o
t
2
0
0
(
4
0
2

.

.

.

)
2
0
4
o
t
1
8
0
(
1
4
2

.

.

.

)
8
4
2
(
2
7
8

.

.

)
8
1
3
(
7
8
8

.

.

)
9
7
4
(
1
6
5
2

.

.

)
9
6
4
(
1
4
7
2

.

.

)
5
5
4
1
(
5
9
1
0
1

.

.

)
1
1
6
(
6
2
1
2

.

.

)
1
1
0
2
(
6
5
3
1
1

.

.

)
6
5
6
(
9
5
4
2

.

0
5
=
n

9
3
=
n

.

)
2
1
6
(
5
1
2
2

.

.

)
9
6
7
(
6
6
4
2

.

.

)
6
2
5
(
9
8
9
1

.

.

)
1
8
5
(
7
7
1
2

.

.

)
3
6
6
(
4
0
2
2

.

.

)
7
7
4
(
3
5
3
2

.

.

)
5
1
4
(
3
9
6
1

.

.

)
5
4
4
(
0
0
9
1

.

0
5
=
n

1
3
=
n

0
5
=
n

8
3
=
n

)
F
E
R
B
-
L
o
Q
O
H
W
(
e
f
i
l

f
o
y
t
i
l
a
u
Q

)

R
S
-
S
D

I
(
n
o
i
s
s
e
r
p
e
D

g
n
i
r
e
d
n
o
p
e
v

i
t
c
e
l
f
e
R

)
S
R
R

(
n
o
i
t
a
n
m
u
R

i

i

g
n
d
o
o
r
B

i

s
p
h
s
n
o
i
t
a
l
e
r
l
a
i
c
o
S

t
n
e
m
n
o
r
i

v
n
E

h
t
l
a
e
h

l
a
c
i
s
y
h
P

l

l
a
c
i
g
o
o
h
c
y
s
P

,
s
t
l
u
s
e
r
t
n
e
m
e
r
u
s
a
e
m
t
s
o
P

)

D
S
(
n
a
e
m
d
e
t
s
u
d
a
n
u

j

s
s
e
n
e
r
a
w
a
h
t
i

w

t
c
A

y
t
i

v

i
t
c
a
e
r
n
o
N

g
n
i
g
d
u
n
o
N

j

e
v
r
e
s
b
O

e
b
i
r
c
s
e
D

)
S
C
S
(
e
l
a
c
S
n
o
i
s
s
a
p
m
o
C
-
f
l
e
S

s
s
e
n
d
n
k
-
f
l
e
S

i

t
n
e
m
g
d
u
j
-
f
l
e
S

)

Q
M
F
F
(
s
l
l
i

l

k
s
s
s
e
n
u
f
d
n
M

i

e
r
i
a
n
n
o
i
t
s
e
u
Q
e
f
i
L
f
o
y
t
i
l
a
u
Q
n
o
i
t
a
s
i
n
a
g
r
O
h
t
l
a
e
H
d
l
r
o
W
L
o
Q
O
H
W
e
l
a
c
S
n
o
i
s
s
a
p
m
o
C
-
f
l
e
S

;

,

,

S
C
S

;
t
r
o
p
e
R
f
l
e
S
-
y
g
o
o
t
a
m
o
t
p
m
y
S
e
v

l

i
s
s
e
r
p
e
D

f
o
y
r
o
t
n
e
v
n
I

,

R
S
-
S
D

I

;

e
r
i
a
n
n
o
i
t
s
e
u
Q
s
s
e
n
u
f
d
n
M

l

i

s
t
e
c
a
F
e
v
F
Q
M
F
F

i

,

.

e
t
o
N

.

)
0
8
4
o
t
6
3
1
(
8
0
3

.

.

.

)
2
2
5
(
2
9
7
1

.

.

)
0
3
4
(
1
5
0
2

.

.

)
8
0
1
o
t
7
2
0
(
7
6
0

.

.

.

)
6
0
1
(
3
7
2

.

.

)
7
0
1
(
9
2
3

.

)
2
4

.

)
8
7

.

.

)
4
1
1
o
t
5
2
0
(
9
6
0

.

.

.

o
t
6
1
0
‚Äì
(
1
3
0

.

.

)
1
2
1
(
1
8
2

.

.

)
7
0
1
(
7
0
3

.

.

)
0
3
1
(
2
9
2

.

.

)
9
1
1
(
6
4
3

.

.

o
t
1
5
0
‚Äì
(
5
0
0
‚Äì

.

.

)
6
3
1
(
9
2
3

.

.

)
2
1
1
(
1
3
3

.

4
6
0

.

1
0
0
0

.

.

5
0
1
1

6
4
0

.

3
1
0
0

.

6
0
0

.

3
5
7
0

.

8
2
0

.

5
5
1
0

.

2
5
6

.

0
1
0

.

6
0
2

.

2
7
0

.

2
0
0
0

.

4
6
0
1

.

.

)
9
0
1
o
t
5
1
0
(
2
6
0

.

.

.

)
7
1
1
o
t
0
3
0
(
3
7
0

.

.

.

)
0
2
1
(
2
1
3

.

)
3
9
.
(
3
7
3

.

2
4
0

.

2
4
0
0

.

7
2
4

.

.

)
6
1
1
(
5
1
3

.

.

)
6
1
1
(
3
6
3

.

0
7
0

.

1
0
0
0

.

0
3
1
1

.

.

)
1
9
0
o
t
1
1
0
(
1
5
0

.

.

.

)
6
0
1
(
3
7
2

.

.

)
7
0
1
(
9
1
3

.

.

)
4
5
0
o
t
9
3
0
‚Äì
(
7
0
0

.

.

.

)
6
3
1
(
9
2
3

.

.

)
6
1
1
(
8
3
3

.

.

)
5
6
4
o
t
7
1
1
(
1
9
2

.

.

.

)
2
2
5
(
3
9
7
1

.

.

)
4
6
4
(
4
5
0
2

.

.

)
3
7
0
o
t
2
1
0
‚Äì
(
1
3
0

.

.

.

)
1
2
1
(
1
8
2

.

)
8
9
.
(
9
0
3

.

y
t
i
n
a
m
u
h
n
o
m
m
o
C

.

)
9
1
1
o
t
9
2
0
(
4
7
0

.

.

.

)
3
9
0
o
t
2
0
0
(
7
4
0

.

.

.

)
3
2
1
o
t
1
3
0
(
8
7
0

.

.

.

)
0
3
1
(
2
9
2

.

.

)
7
2
1
(
2
5
3

.

.

)
0
2
1
(
2
1
3

.

.

)
3
0
1
(
6
6
3

.

.

)
6
1
1
(
5
1
3

.

.

)
1
3
1
(
0
7
3

.

n
o
i
t
a
c
i
f
i
t
n
e
d
i
r
e
v
O

l

s
s
e
n
u
f
d
n
M

i

n
o
i
t
a
l
o
s
I

CLADDER-MICUS ET AL.

921

Sensitivity analyses using the LOCF sample led to similar findings.

When participants who refused to take antidepressant medication
(n = 5) were excluded from the analyses, results of the ITT sample (‚Äì
3.01, 95% CI [‚Äì6.8, 0.78], d = 0.31, P = 0.12) and the PP sample (‚Äì4.59,
95% CI [‚Äì8.8, ‚Äì0.38], d = 0.51, P = 0.03) were comparable to the main

analyses.

3.3

Secondary outcomes

Compared to TAU, a significantly larger proportion of MBCT + TAU
participants reached remission (MBCT + TAU: 41.5%; TAU: 21.6%,

Table 4). However, most cases were classified as partial remission
(MBCT + TAU: 39.0%; TAU: 17.65%) and a minority as full remission
(MBCT + TAU: 2.44%; TAU: 3.92%). Compared to TAU, the MBCT +
TAU condition showed significantly less rumination (d = 0.39, P = 0.04)
and significantly higher quality of life (d = 0.42, P = 0.048) at posttreat-

ment, controlling for baseline scores. Additionally, participants with
MBCT + TAU showed significantly more mindfulness skills (d = 0.73,
P < 0.001) and significantly more self-compassion (d = 0.64, P = 0.001)

more participants in the MBCT + TAU condition reached partial
remission and MBCT + TAU participants reported less rumination

and increased quality of life, mindfulness skills, and self-compassion

compared to participants receiving TAU only.

The finding that the decrease in depressive symptoms was signif-

icant only in the PP analysis and not in the ITT analysis can be partially

explained by the relatively high proportion of patients not completing
MBCT (n = 12, 24.5%). This percentage is comparable to other studies

on MBCT in chronic (27.8%; Michalak, Schultze, Heidenreich, &

Schramm, 2015) or pharmacoresistant depressed patients (22.98%;

Eisendrath et al., 2016), but seems to be higher than in studies

focusing on patients with recurrent depression (8.8%; van Aalderen

et al., 2011). Compared to completers, non-completers reported a

shorter duration of the current depressive episode and were more

often unemployed. This could indicate that a longer duration might

increase psychological burden and thereby motivates patients to

acquire new skills. Additionally, a daily routine could be helpful in

incorporating mindfulness skills into daily life. However, the sample of

non-completers is too small to draw firm conclusions here. Although

than participants with TAU only. Analyses in the PP sample yielded

one might expect that the most severely depressed patients drop out

comparable results (see Tables 3 and 4).

3.4 Moderation analyses

There were no significant moderators for the effect of condition on

depressive symptoms in the ITT sample, apart from baseline levels of
rumination (F (1, 84) = 5.44, P = 0.02). Participants with higher baseline

rumination showed a significantly larger decrease in depressive symp-
toms in the MBCT + TAU condition compared to TAU, while controlling

for depressive symptoms on baseline. In an exploratory analysis, par-

ticipants were grouped based on a previously published clinical mean

of the RRS-EXT (Raes et al., 2009). In the group of participants scoring

above the clinical mean for rumination, participants assigned to MBCT
+ TAU showed significantly lower depressive symptoms compared to
TAU (‚Äì10.79, 95% CI [‚Äì15.72 to ‚Äì5.85], d = 1.64, P < 0.001; MBCT +
TAU n = 17, TAU n = 22) posttreatment while controlling for baseline
depressive symptoms, whereas no difference between MBCT + TAU

and TAU was observed in the group of participants scoring below the
clinical mean (1.47, 95% CI [‚Äì4.38 to 7.33], d = 0.24, P = 0.62; MBCT +
TAU n = 22, TAU n = 30). Patients of the MBCT + TAU condition who

scored high on treatment resistance (DM-TRD) tended to report higher

levels of depressive symptoms posttreatment, however this difference
was not significant (F (1, 89) = 3.05, P = 0.084).

4

DISCUSSION

The aim of the current study was to investigate the effectiveness of
MBCT + TAU for chronic, treatment-resistant depressed patients, who

of treatment, non-completers and completers did not differ in the

severity of depressive symptoms, number of previous episodes, or age

of onset. By contrast, a noticeable number of non-completers reported

that physical problems (see Figure 1) interfered with participation and

were the reason for discontinuing MBCT.

MBCT + TAU had significant effects on rumination, quality of life,

mindfulness skills, and self-compassion. Following the course, MBCT
+ TAU participants reported less rumination and a higher quality of

life. The increase in mindfulness skills and self-compassion might indi-

cate that chronic, treatment-resistant depressed patients are able to

learn mindfulness meditation techniques and develop a more compas-

sionate and friendlier attitude toward themselves. Although results

of these secondary outcomes should be interpreted as preliminary, as

the power analysis was focused on changes in depressive symptoms,
this may indicate that MBCT + TAU has effects that could be valuable

for chronic, treatment-resistant depressed patients, even if no or only

small changes in depressive symptoms are evoked.

This study is the first to investigate the effectiveness of MBCT +

TAU for chronic, treatment-resistant depressed patients who did not

benefit from pharmacotherapy and psychological treatment. The cur-

rent study has high ecological validity because of its pragmatic design.

Participants were moderately to severely depressed outpatients and

were enrolled in MBCT trainings provided regularly at their local men-

tal health care institution. Thereby this study provides much-needed

insight into the effectiveness rather than efficacy of MBCT, which was

formulated as an important research goal in a recent review paper

of MBCT (Dimidjian & Segal, 2015). However, the effect sizes found
in this study (ITT: d = 0.35; PP: d = 0.45) are smaller than in previ-

ous preliminary studies of chronic or treatment-resistant depressed

had not improved during not only previous pharmacotherapy but also

patients (Barnhofer et al., 2009; Eisendrath et al., 2008; Kenny &

psychological treatment. The results of the ITT analysis did not confirm

the expected reduction in depressive symptoms. However, completers
of the MBCT + TAU did show a significant decrease in depressive

Williams, 2007), as well as smaller than the effect size found in previ-
ous research on currently depressed patients (d = 0.53; van Aalderen

et al., 2011), which was used for our power analysis. Both the relatively

symptoms compared to TAU. Further, according to the ITT analyses,

small effect size and the high drop-out rate from MBCT can likely be

922

CLADDER-MICUS ET AL.

TA B L E 4 Number (and percentages) of depression status at posttreatment according to DSM-IV criteria

ITT

MBCT + TAU TAU

PP

MBCT + TAU TAU

n = 41

n = 51

ùùå 2 test

n = 34

n = 51

ùùå 2 test

Major depression

24 (58.5)

40 (78.4)

ùúí 2(2) = 4.25, P = 0.039, ùúë = 0.22

19 (55.9)

40 (78.4)

ùúí 2(2) = 4.89, P = 0.027, ùúë = 0.24

Remission

17 (41.5)

11 (21.6)

Full remission

1 (2.44)

Partial remission

16 (39.0)

2 (3.92)

9 (17.65)

15 (44.1)

11 (21.6)

0 (0)

2 (3.92)

15 (44.14)

9 (17.65)

Note. Remission is defined as reporting no DSM-IV symptoms of depression during the last 2 weeks based on the MINI. Partial remission is defined as report-
ing some symptoms but not fulfilling DSM-IV criteria for a major depressive disorder. Depression is defined as fulfilling the DSM-IV criteria for major depres-
sion on the MINI.

explained by the higher severity of symptoms in the current study sam-

ization. Participants who had to wait more than 4 weeks until the

ple compared to previous research (van Aalderen et al., 2011). As only

start of MBCT received a second baseline assessment. This means

completers showed a significant decrease in depressive symptoms,

that the total duration of the study is not identical for the conditions.

obstacles to completing treatment should be investigated in future

However, one should note that we found no difference in depressive

research, for example, by conducting qualitative interviews.

symptoms between the first and second baseline assessment. In

In addition to the effectiveness of MBCT, we also investigated pos-

addition, research designs investigating potential mediators such

sible moderators of treatment effect. Importantly, levels of rumination
moderated the effect of MBCT + TAU compared to TAU on depres-

as rumination, mindfulness skills, and self-compassion by including

multiple assessments during the course of MBCT would give further

sive symptoms. Participants with high levels of rumination benefit-
ted more from MBCT + TAU than TAU. According to the underlying

insight into mechanisms of change.

The current study provides several clinical and research implica-

theoretical model, rumination is an important working mechanism of

tions. Even though effects on depressive symptoms were not sig-

MBCT (Segal et al., 2002) and previous work has indicated that rumina-

nificant in the ITT analysis, results of the secondary outcome mea-

tion might mediate the effect of MBCT on depressive symptoms (Sha-

sures indicated that MBCT might have beneficial effects for chronic,

har, Britton, Sbarra, Figueredo, & Bootzin, 2010; van der Velden et al.,

treatment-resistant patients on important factors other than depres-

2015). The current study indicates that MBCT could be particularly

helpful for chronic, treatment-resistant depressed patients with high

sive symptoms. In addition, the results of the PP analyses indicated that
completers of MBCT + TAU did show a significantly greater reduction

levels of rumination. However, because of the explorative nature of

in depressive symptoms compared to TAU alone. Keeping in mind that

the moderation analysis, this finding should be interpreted as prelimi-

the study sample represents a seriously ill population, small effects

nary and requires replication and further investigation. In addition, the

on depressive symptoms accompanied by effects on rumination, qual-

results of the current study showed no moderating effects of childhood

ity of life, mindfulness, and self-compassion may be valuable for an

trauma, baseline severity of depression, chronicity, or treatment resis-

individual patient. In addition, the relatively low costs and rare side

tance. Moderating effects of childhood trauma and severity of base-

effects of MBCT compared with other treatment options for this pop-

line symptoms were previously found in recurrent depressed patients

ulation, for example, intensive pharmacological treatment or electro-

(Ma & Teasdale, 2004; Williams et al., 2014). However, recent studies

convulsive therapy, should be taken into account in treatment choice.

on MBCT in chronic or pharmacoresistant depression found no moder-

However, it seems to be important to further investigate reasons why

ating effect of these variables (Eisendrath et al., 2016; Michalak et al.,

patients do not complete MBCT. Additionally, future research should

2016), which is in line with our findings. Taken together, these results

further focus on rumination and other possible working mechanisms

indicate that rumination might be an important moderator in chronic,

in order to provide researchers and clinicians with more information

treatment-resistant depression, while levels of childhood trauma and

about the working mechanisms of MBCT and predictors of treatment

severity of depressive symptoms at baseline appear to be of less

success.

influence.

A limitation of the current study is that MBCT was implemented
as an add-on to TAU. The results in the MBCT + TAU condition could

ACKNOWLEDGMENTS

therefore be partially due to nonspecific therapy effects, such as peer

This research was partly funded by a grant from Fonds Psychis-

support, hope, and attention received from the therapist. Additionally,

che Gezondheid, the Netherlands Foundation for Mental Health

patients and investigators were not blind to treatment allocation,

(number 2011 6630). The funder had no role in the conduct of the

which might have been a potential source of bias. Future studies

study, data collection, analysis, interpretation of results, or prepara-

should compare MBCT to active treatments matched on treatment

tion of the manuscript. The authors would like to thank the partici-

intensity and should also investigate long-term effects and cost effec-

pants for their willingness to take part in the trial. We would also like

tiveness. Furthermore, due to the pragmatic design of the study, MBCT

to thank the mindfulness trainers for providing the training, and Hiske

trainings were not in all cases immediately available after random-

van Ravesteijn, Melanie Schellekens, and Lotte School for independent

CLADDER-MICUS ET AL.

923

ratings of the data. In addition, we would like to acknowledge and thank

Mark Mepschen, Renske Olearnik, Peter Delsink, Veroniek Vugts, Ros-

alie van Woezik, Denise te Paste, Anja Calaminus, Peter Janssen, Tessa

Heijnen, Charlotte van den Beuken, Sophie Bekmann, and Nadera Aga

for helping with recruitment and data collection. We would like to

thank Julie Krans for helpful comments on a previous version of the

manuscript.

CONFLICT OF INTEREST

A.E.M. Speckens is founder and clinical director of the Radboudumc

Centre for Mindfulness. She is a mindfulness trainer and occasionally

receives payment for training workshops and presentations related to

mindfulness-based cognitive therapy. She also donates all such fees to

Radboud University Medical Center. M.B. Cladder-Micus, J. Spijker, E.S.

Becker, J.N. Vrijsen, and A.R.T. Donders declare they have no potential

conflict of interest.

ORCID

Mira B. Cladder-Micus

http://orcid.org/0000-0003-4304-9202

Janna N. Vrijsen

http://orcid.org/0000-0002-7081-9893

REFERENCES

Baer, R. A., Smith, G. T., Lykins, E., Button, D., Krietemeyer, J., Sauer, S., ‚Ä¶
Williams, J. M. G. (2008). Construct validity of the five facet mindful-
ness questionnaire in meditating and nonmeditating samples. Assess-
ment, 15(3)329‚Äì342.

Barnhofer, T., Crane, C., Hargus, E., Amarasinghe, M., Winder, R., & Williams,
J. M. G. (2009). Mindfulness-based cognitive therapy as a treatment for
chronic depression: A preliminary study. Behaviour Research and Ther-
apy, 47(5), 366‚Äì373. https://doi.org/10.1016/j.brat.2009.01.019

Bernstein, D. P., Stein, J. A., Newcomb, M. D., Walker, E., Pogge, D., Ahluvalia,
T., ‚Ä¶ Zule, W. (2003). Development and validation of a brief screening
version of the Childhood Trauma Questionnaire. Child Abuse and Neglect,
27(2), 169‚Äì190. https://doi.org/10.1016/s0145-2134(02)00541-0

Cladder-Micus, M. B., Vrijsen, J. N., Becker, E. S., Donders, R., Spijker, J., &
Speckens, A. E. (2015). A randomized controlled trial of mindfulness-
based cognitive therapy (MBCT) versus treatment-as-usual (TAU) for
chronic, treatment-resistant depression: Study protocol. BMC Psychia-
try, 15(1), 1‚Äì8.

Crane, R. S., Kuyken, W., Williams, J. M. G., Hastings, R. P., Cooper, L., &
Fennell, M. J. V. (2012). Competence in teaching mindfulness-based
courses: Concepts, development and assessment. Mindfulness, 3(1), 76‚Äì
84. https://doi.org/10.1007/s12671-011-0073-2

Fekadu, A., Wooderson, S., Donaldson, C., Markopoulou, K., Masterson, B.,
Poon, L., & Cleare, A. J. (2009). A multidimensional tool to quantify treat-
ment resistance in depression: The Maudsley staging method. The Jour-
nal of Clinical Psychiatry, 70(2), 177‚Äì184.

Fekadu, A., Wooderson, S. C., Markopoulou, K., & Cleare, A. J. (2009). The
Maudsley staging method for treatment-resistant depression: Predic-
tion of longer-term outcome and persistence of symptoms. The Journal
of Clinical Psychiatry, 70(7), 952‚Äì957.

Geschwind, Peeters, Huibers, van Os, & Wichers (2012). Efficacy of
mindfulness-based cognitive therapy in relation to prior history of
depression: Randomised controlled trial. The British Journal of Psychia-
try, 201(4), 320‚Äì325. https://doi.org/10.1192/bjp.bp.111.104851

Kenny, M. A., & Williams, J. M. G. (2007). Treatment-resistant depressed
patients
show a good response to mindfulness-based cogni-
tive therapy. Behaviour Research and Therapy, 45(3), 617‚Äì625.
https://doi.org/10.1016/j.brat.2006.04.008

Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K.
R., ‚Ä¶ Wang, P. S. (2003). The epidemiology of major depressive disor-
der: Results from the National Comorbidity Survey Replication (NCS-R).
Jama, 289(23), 3095‚Äì3105.

Kuyken, W., Warren, F. C., Taylor, R. S., Whalley, B., Crane, C., Bon-
dolfi, G., ‚Ä¶ Dalgleish, T. (2016). Efficacy of mindfulness-based cog-
nitive therapy in prevention of depressive relapse: An individual
patient data meta-analysis from randomized trials. JAMA Psychiatry,
https://doi.org/10.1001/jamapsychiatry.2016.0076

Lopez, A. D., Mathers, C. D., Ezzati, M., Jamison, D. T., & Murray, C. J. (2006).
Global and regional burden of disease and risk factors, 2001: Systematic
analysis of population health data. The Lancet, 367(9524), 1747‚Äì1757.

Ma, S. H., & Teasdale, J. D. (2004). Mindfulness-based cognitive therapy for
depression: Replication and exploration of differential relapse preven-
tion effects. Journal of Consulting and Clinical Psychology, 72(1), 31‚Äì40.
https://doi.org/10.1037/0022-006x.72.1.31

McCullough, J. P. (2003). Treatment for chronic depression using cognitive
behavioral analysis system of psychotherapy (CBASP). Journal of Clinical
Psychology, 59(8), 833‚Äì846.

Michalak, J., Probst, T., Heidenreich, T., Bissantz, N., & Schramm, E. (2016).
Mindfulness-based cognitive therapy and a group version of the cog-
nitive behavioral analysis system of psychotherapy for chronic depres-
sion: Follow-up data of a randomized controlled trial and the moder-
ating role of childhood adversities. Psychotherapy and Psychosomatics,
85(6), 378‚Äì380.

Michalak, J., Schultze, M., Heidenreich, T., & Schramm, E. (2015). A
randomized controlled trial on the efficacy of mindfulness-based
cognitive therapy and a group version of cognitive behavioral anal-
ysis system of psychotherapy for chronically depressed patients.
Journal of Consulting and Clinical Psychology, 83(5), 951‚Äì963.
https://doi.org/10.1037/ccp0000042

Cuijpers, P., Huibers, M. J., & Furukawa, T. A. (2017). The need for research
on treatments of chronic depression. JAMA Psychiatry, 74, 242‚Äì243.

Neff, K. D. (2003). The development and validation of a scale to measure

self-compassion. Self and Identity, 2(3), 223‚Äì250.

Dimidjian, S., & Segal, Z. V. (2015). Prospects for a clinical science of
mindfulness-based intervention. American Psychologist, 70(7), 593.

DSM-IV-TR, A. (2000). Diagnostic and statistical manual of mental disorders-

text revision. Washington, DC: American Psychiatric Association.

Eisendrath, S. J., Delucchi, K., Bitner, R., Fenimore, P., Smit, M., & McLane, M.
(2008). Mindfulness-based cognitive therapy for treatment-resistant
depression: A pilot study. Psychotherapy and Psychosomatics, 77(5), 319‚Äì
320. https://doi.org/10.1159/000142525

Eisendrath, S. J., Gillung, E., Delucchi, K. L., Segal, Z. V., Nelson, J. C.,
McInnes, L. A., ‚Ä¶ Feldman, M. D. (2016). A randomized controlled trial
of mindfulness-based cognitive therapy for treatment-resistant depres-
sion. Psychotherapy and Psychosomatics, 85(2), 99‚Äì110.

Network, U. M.-B. T. T.

(2011). Good practice guidance for teach-
ers. Retrieved from https://mindfulnessteachersuk.org.uk/pdf/teacher-
guidelines.pdf

NICE. (2009). Depression: The treatment and management of depression in
adults (updated edition). Leicester, England: British Psychological Society.
Retrieved from www.nice.org.uk/CG90

Peeters, F. P., Ruhe, H. G., Wichers, M., Abidi, L., Kaub, K., van der Lande, H. J.,
‚Ä¶ Schene, A. H. (2016). The Dutch Measure for quantification of Treat-
ment Resistance in Depression (DM-TRD): An extension of the Mauds-
ley Staging Method. Journal of Affective Disorders, 205, 365‚Äì371.

Petersen, T., Papakostas, G. I., Posternak, M. A., Kant, A., Guyker, W. M.,
Iosifescu, D. V., ‚Ä¶ Fava, M. (2005). Empirical testing of two models

924

CLADDER-MICUS ET AL.

for staging antidepressant treatment resistance. Journal of Clinical Psy-
chopharmacology, 25(4), 336‚Äì341.

Pincus, H. A. H. (2001). The societal costs of chronic major depression. Jour-

nal of Clinical Psychiatry, 62, 5‚Äì9.

Raes, F., & Hermans, D. (2007). The revised version of the Dutch ruminative

response scale (Unpublished instrument).

Raes, F., Schoofs, H., Hoes, D., Hermans, D., Van Den Eede, F., & Franck,
‚ÄôReflection'en'brooding'als subtypes van rumineren: Een
E. (2009).
herziening van de Ruminative Response Scale. Gedragstherapie, 42(3/4),
205‚Äì214.

Rush, A. J., Gullion, C. M., Basco, M. R., Jarrett, R. B., & Trivedi, M. H. (1996).
The inventory of depressive symptomatology (IDS): Psychometric prop-
erties. Psychological Medicine, 26(3), 477‚Äì486.

Rush, A. J., Thase, M. E., & Dub√©, S. (2003). Research issues in the study of
difficult-to-treat depression. Biological Psychiatry, 53(8), 743‚Äì753.

Shahar, B., Britton, W. B., Sbarra, D. A., Figueredo, A. J., & Bootzin, R. R.
(2010). Mechanisms of change in mindfulness-based cognitive ther-
apy for depression: Preliminary evidence from a randomized controlled
trial. International Journal of Cognitive Therapy, 3(4), 402‚Äì418.

Schoofs, H., Hermans, D., & Raes, F. (2010). Brooding and reflection as sub-
types of rumination: Evidence from confirmatory factor analysis in non-
clinical samples using the Dutch Ruminative Response Scale. Journal of
Psychopathology and Behavioral Assessment, 32(4), 609‚Äì617.

Segal, Z. V., Williams, J., & Teasdale, J. (2002). Mindfulness-based cognitive
therapy for depression: A new approach to relapse prevention. New York,
NY: Guilford Press.

Segal, Z. V., Williams, J. M. G., & Teasdale (2012). Mindfulness-based cognitive

therapy for depression. New York, NY: Guilford Press.

Sheehan, D. V., Lecrubier, Y., Sheehan, K. H., Amorim, P., Janavs, J., Weiller, E.,
‚Ä¶ Dunbar, G. C. (1998). The Mini-International Neuropsychiatric Inter-
view (MINI): The development and validation of a structured diagnostic
psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychia-
try, 59, 22‚Äì33.

Skevington, S. M., Lotfy, M., & O'Connell, K. A. (2004). The World Health
Organization's WHOQOL-BREF quality of life assessment: Psychome-
tric properties and results of the international field trial. A report from
the WHOQOL group. Quality of Life Research, 13(2), 299‚Äì310.

Souery, D., Amsterdam, J., De Montigny, C., Lecrubier, Y., Montgomery,
S., Lipp, O., ‚Ä¶ Mendlewicz, J. (1999). Treatment resistant depression:
Methodological overview and operational criteria. European Neuropsy-
chopharmacology, 9(1), 83‚Äì91.

population: Results from The Netherlands Mental Health Survey and
Incidence Study (NEMESIS). The British Journal of Psychiatry, 181(3),
208‚Äì213.

Strauss, C., Cavanagh, K., Oliver, A., & Pettman, D. (2014). Mindfulness-
based interventions for people diagnosed with a current episode of
an anxiety or depressive disorder: A meta-analysis of randomised con-
trolled trials. PLoS One, 9(4), e96110.

Thase, M. E., & Rush, A. J. (1997). When at first you don't succeed: Sequen-
tial strategies for antidepressant nonresponders. The Journal of Clinical
Psychiatry, 58, 23‚Äì29.

Torpey, D. C., & Klein, D. N. (2008). Chronic depression: Update on classifi-

cation and treatment. Current Psychiatry Reports, 10(6), 458‚Äì464.

Trevino, K., McClintock, S. M., Fischer, N. M., Vora, A., & Husain, M.
M. (2014). Defining treatment-resistant depression: A comprehensive
review of the literature. Annals of Clinical Psychiatry, 26(3), 222‚Äì232.

van der Velden, A. M., Kuyken, W., Wattar, U., Crane, C., Pallesen, K. J., Dahl-
gaard, J., ‚Ä¶Piet, J. (2015). A systematic review of mechanisms of change
in mindfulness-based cognitive therapy in the treatment of recurrent
major depressive disorder. Clinical psychology review, 37, 26‚Äì39.

van Aalderen, J. R., Donders, A. R. T., Giommi, F., Spinhoven, P., Baren-
dregt, H. P., & Speckens, A. E. M. (2011). The efficacy of mindfulness-
based cognitive therapy in recurrent depressed patients with and
without a current depressive episode: A randomized controlled trial.
Psychological Medicine, 42(05), 989‚Äì1001. https://doi.org/10.1017/
s0033291711002054

Williams, J. M. G., Crane, C., Barnhofer, T., Brennan, K., Duggan, D. S., Fennell,
M. J. V., ‚Ä¶ Russell, I. T. (2014). Mindfulness-based cognitive therapy for
preventing relapse in recurrent depression: A randomized dismantling
trial. Journal of Consulting and Clinical Psychology, 82, 275‚Äì286.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Support-

ing Information section at the end of the article.

How to cite this article: Cladder-Micus MB, Speckens AEM,

Vrijsen JN, Donders ART, Becker ES, Spijker J. Mindfulness-

based cognitive therapy for patients with chronic, treatment-

resistant depression: A pragmatic randomized controlled trial.

Depress Anxiety. 2018;35:914‚Äì924. https://doi.org/10.1002/

Spijker, J., De Graaf, R., Bijl, R. V., Beekman, A. T., Ormel, J., & Nolen,
W. A. (2002). Duration of major depressive episodes in the general

da.22788
